The abstract is read at the publisher; the summary is JClub's.
In advanced lung cancer patients receiving radio-immunotherapy, radiation-induced TET2 expression in myeloid-derived suppressor cells correlates with poor outcomes.
- Why it matters: Radiation can trigger immunosuppressive myeloid programs that contribute to therapeutic resistance and metastasis, limiting the effectiveness of radiotherapy plus immunotherapy.
- What they did: After radiotherapy, myeloid-specific Tet2 deletion in the model system suppresses tumor progression and shifts monocyte differentiation toward antigen-presenting MDACs; mapping shows this fate program initiates rapidly in bone marrow.
- The result: A p53–TET2 axis reduces m5C on chromatin-associated RNAs to enforce immunosuppressive chromatin compaction and interferon silencing, while Tet2 loss or pharmacologic TET2 inhibition restores accessibility, boosts CD8 T cell cytotoxicity, and augments radiotherapy and PD-L1 blockade against primary and metastatic tumors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.